Characterization of a non-paralyzing bont-based biopharmaceutical for the treatment of neuropathic pain
Active Awarded Last action
- Contract number
- 75N95021F00001
- Awardee
-
Lovelace Biomedical Research Institute UEI MBT9RXJJ7428
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,633,884
Award facts
- Opportunity
-
- 75N95021R00045 Solicitation number
- Contract value 81% obligated
-
- $1,633,884.00 Current, with exercised options
- $2,011,289.00 Potential, with all options
- Completion date 88% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Albuquerque, NM 87108, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $350,840 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $127,947 | |
| Supplemental Agreement for work within scope | $499,589 | |
| Supplemental Agreement for work within scope | $71,465 | |
| Original award | $584,043 |
About this award
The National Institute on Drug Abuse issued a delivery order to Lovelace Biomedical Research Institute on September 24, 2021, with a ceiling value of $2.011 million for characterization of a non-paralyzing botulinum toxin-based biopharmaceutical for treatment of neuropathic pain.
Work is performed in Albuquerque, New Mexico under Cost Plus Fixed Fee pricing. The order is scheduled for completion June 30, 2027. Lovelace self-performed all reported labor through FY2024, executing 1.2 FTEs and 2,400 contractor hours at a derived rate of $146.44 per hour. Labor footprint grew from 0.3 FTEs in FY2022 to 1.2 FTEs by FY2024, with corresponding increases in contractor hours.
Quick answers
Who was awarded contract 75N95021F00001?
75N95021F00001 was awarded to Lovelace Biomedical Research Institute by National Institute on Drug Abuse (National Institutes of Health) on September 24, 2021.
How much is contract 75N95021F00001 worth?
The government has obligated $1,633,884 on 75N95021F00001. Its potential value, with all options, is $2,011,289.
Is contract 75N95021F00001 an order under another contract?
Yes. 75N95021F00001 is a delivery order under 75N95019D00012, an indefinite delivery contract.
Was contract 75N95021F00001 competed?
The extent of competition for 75N95021F00001 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award